Characteristics and outcomes of COVID-19 patients presumed to be treated with sotrovimab in NHS hospitals in England

Table 2 Patient characteristics

Characteristic	Patients (n = 10,096)
Age, years
Mean (SD)	56.40 (16.4)
Median (IQR)	57 (44–69)
Age group, years, n (%)
12–54	4412 (43.7)
55–64	2278 (22.6)
65–74	1961 (19.4)
≥ 75	1445 (14.3)
Female sex, n (%)	4238 (42)
Ethnicity, n (%)^a
White	6955 (68.9)
Asian/Asian British	619 (6.1)
Black/Black British/Caribbean or African	239 (2.4)
Mixed	114 (1.1)
Other	329 (3.3)
Unknown	1840 (18.2)
Previous admission for COVID-19, n (%)	298 (3.0)
High-risk comorbidities, n (%)^c
Active cancer	910 (9.0)
Down syndrome	107 (1.1)
HIV	^b
Immune deficiencies^d	338 (3.3)
Patients being treated for immune-mediated inflammatory disorders^e	4337 (43.0)
Patients with hematologic diseases and stem cell transplant recipients	602 (6.0)
Patients with liver disease	438 (4.3)
Rare neurologic conditions^f	1053 (10.4)
Severe renal disease	1422 (14.1)
Solid organ transplant recipients	280 (2.8)
No comorbidity, n (%)	2633 (26.1)

^a Percentages calculated based on removal of “unknown” group from the denominator;
^b Small number suppression applied
^c As defined by the UK Medicines & Healthcare products Regulatory Agency [13]
^d common variable immunodeficiency; undefined primary antibody deficiency on immunoglobulin (or eligible for IgG); hyper-IgM syndromes; Good’s syndrome; severe combined immunodeficiency; autoimmune polyglandular syndromes/autoimmune polyendocrinopathy, ectodermal dystrophy; primary immunodeficiency associated with impaired type I interferon signalling; X-linked agammaglobulinaemia (and other primary agammaglobulinaemias); any patient with a secondary immunodeficiency likely to be eligible for receipt of immunoglobulin replacement therapy
^e IMID treated with rituximab or other B cell depleting therapy in the last 12 months; IMID with active/unstable disease on corticosteroids, cyclophosphamide, tacrolimus, cyclosporin or mycophenolate; IMID with stable disease on either corticosteroids, cyclophosphamide, tacrolimus, cyclosporin or mycophenolate; IMID patients with active/unstable disease including those on biological monotherapy and on combination biologicals with thiopurine or methotrexate
^f multiple sclerosis; motor neurone disease; myasthenia gravis; Huntington’s disease
COVID-19, coronavirus disease 2019; HIV, human immunodeficiency virus; IMID, immune-mediated inflammatory disorders; IQR, interquartile range; SD, standard deviation

ISSN: 1471-2334